The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of neoadjuvant chemotherapy with bevacizumab plus mFOLFOX6 for resectable synchronous liver metastasis (SLM) from colorectal cancer: The first report of the Miyagi Hepato-Biliary Pancreatic Clinical Oncology Group.
Yu Katayose
No relevant relationships to disclose
Junichiro Yamauchi
No relevant relationships to disclose
Masaya Oikawa
No relevant relationships to disclose
Naoki Sakurai
No relevant relationships to disclose
Hiroaki Musya
No relevant relationships to disclose
Hiromune Shimamura
No relevant relationships to disclose
Koh Miura
No relevant relationships to disclose
Kei Nakagawa
No relevant relationships to disclose
Shinichi Egawa
No relevant relationships to disclose
Michiaki Unno
No relevant relationships to disclose